(Q40410230)

20 September 2017

Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer (English)

1 reference

20 September 2017

Shulin Li

1

1 reference

20 September 2017

Lijie Zhang

2

1 reference

20 September 2017

Marina Torrero

3

1 reference

20 September 2017

Martin Cannon

4

1 reference

20 September 2017

Robin Barret

5

1 reference

20 September 2017

13 June 2005

1 reference

20 September 2017

1 reference

20 September 2017

12

1 reference

20 September 2017

5

1 reference

20 September 2017

942-949

1 reference

Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12.

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Applications of muscle electroporation gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

In vivo gene electroporation of glial cell line-derived neurotrophic factor (GDNF) into skeletal muscle of SOD1 mutant mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

IL-12 deaths: explanation and a puzzle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Regulation of human cytolytic lymphocyte responses by interleukin-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Interleukin-12: a cytokine at the interface of inflammation and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Regression of tumors by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Nonviral interferon alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Optimal salt concentration of vehicle for plasmid DNA enhances gene transfer mediated by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Rapid recruitment of macrophages in interleukin-12-mediated tumour regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

Role of IL12 as an anti-tumour agent: current status and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.037

10.1016/J.YMTHE.2005.03.037

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference